Phosphorus Is Part Of A Ring Patents (Class 514/110)
  • Patent number: 10131952
    Abstract: Disclosed herein are compositions and methods for monitoring hematopoietic reconstitution or suppression in a subject. Also disclosed are compositions and methods for reconstituting the hematopoietic compartment of a subject in need thereof. Also disclosed is a method for monitoring the effect of ionizing radiation on the lung in a subject. Also disclosed is the ability to use detection of the one or more microRNA indicative of radiation-induced lung injury to guide therapy of the subject. Also disclosed is the ability to use detection of the one or more microRNA indicative of radiation-induced lung injury to evaluate the efficacy of a lung treatment following radiation exposure.
    Type: Grant
    Filed: May 14, 2015
    Date of Patent: November 20, 2018
    Assignee: Ohio State Innovation Foundation
    Inventors: Naduparambil Jacob, Arnab Chakravarti
  • Patent number: 9913812
    Abstract: Methods of treating skin neoplasms using a monoamine oxidase inhibitor, e.g., a propynylaminoindan (such as rasagiline) are provided. Pharmaceutical compositions and kits comprising monoamine oxidase inhibitors are also provided.
    Type: Grant
    Filed: November 2, 2012
    Date of Patent: March 13, 2018
    Assignee: Teikoku Pharma USA, Inc.
    Inventors: Susan Meier-Davis, Jianye Wen, Richard D. Hamlin
  • Patent number: 9611313
    Abstract: Methods of inhibiting the growth of tumors comprising administering chimeric fusion molecules comprising endostatin mutants and all or a portion of anti-Her2 or anti-EGFR antibodies.
    Type: Grant
    Filed: April 16, 2014
    Date of Patent: April 4, 2017
    Assignee: UNIVERSITY OF MIAMI
    Inventors: Seung-Uon Shin, Joseph David Rosenblatt, Sherie L. Morrison
  • Patent number: 9540326
    Abstract: Disclosed herein are prolyl hydroxylase inhibitors that can stabilize hypoxia inducible factor-1 alpha (HIF-1?), as well as hypoxia inducible factor-2 (HIF-2). Also disclosed herein are pharmaceutical compositions comprising one or more of the disclosed compounds. Yet further disclosed are methods for stimulating the cellular immune response in a mammal such as increasing phagocytosis, for example, prolonging the life of phagocytes, inter alia, kerotyiocytes, neutrophils. As such the disclosed compounds provide methods for treating diseases that relate to the body's immune response.
    Type: Grant
    Filed: April 16, 2015
    Date of Patent: January 10, 2017
    Assignee: AERPIO THERAPEUTICS, INC.
    Inventors: Joseph H. Gardner, Robert Shalwitz
  • Patent number: 9340563
    Abstract: Disclosed herein are crystalline compounds of formula (I) wherein A+ represents a hydroxylated aliphatic ammonium species; and X and Y independently represent leaving groups.
    Type: Grant
    Filed: November 6, 2013
    Date of Patent: May 17, 2016
    Assignee: ZIOPHARM Oncology, Inc.
    Inventors: John C. Amedio, Jr., Barbara Wallner, Philip B. Komarnitsky
  • Publication number: 20150132408
    Abstract: The present invention provides sorafenib analogs for use in a method of treating a disease mediated by p21, said method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula I. The present invention also provides methods of inhibiting p21 in a cell comprising contacting the cell with an effective amount of a compound of formula I.
    Type: Application
    Filed: June 20, 2013
    Publication date: May 14, 2015
    Inventors: Robert H. Weiss, Bruce D. Hammock, Hiromi Inoue, Sung Hee Hwang
  • Publication number: 20150126478
    Abstract: An Accelerated Progression Relapse Test (APRT) and method is provided for use in the prognosis of a patient having an ER+ breast cancer. The APRT provides a determination of when a patient in a particular diseased state is likely to benefit from further disease treatment, or does not have a high probability of benefit with additional treatment. Four genetic probes are disclosed that target the MK167, CDC6 and SPAG5 gene and gene products. The ER+ breast cancer patient population is stratified into two groups, with the low gene expression group identifying the patient/patient group that is less likely to benefit from additional treatment measures, and a high gene expression group identifying the patient group that is more likely to benefit from additional treatment measures.
    Type: Application
    Filed: November 1, 2013
    Publication date: May 7, 2015
    Inventor: Steven Buechler
  • Publication number: 20150104384
    Abstract: The present invention relates to certain amido-benzyl sulfoxide and sulfone compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.
    Type: Application
    Filed: March 1, 2013
    Publication date: April 16, 2015
    Inventors: Kenneth W. Bair, Timm R. Baumeister, Alexandre J. Buckmelter, Karl H. Clodfelter, Peter Dragovich, Francis Gosselin, Janet Gunzner-Toste, Bingsong Han, Jian Lin, Xiongcai Liu, Dominic J. Reynolds, Chase C. Smith, Zhongguo Wang, Mark Zak, Yamin Zhang, Guiling Zao, Xiaozhang Zheng, Po-Wai Yuen
  • Publication number: 20150071874
    Abstract: Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms or sequelae of disease. Chronic and acute conditions may be due to viral infections such as HIV and AIDS, neoplastic diseases stroke, kidney disease, urinary incontinence, autoimmune disorders, Parkinson's disease, prostate hypertrophy, aging, or the treatment of such diseases. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent to yield more effective treatment tools against acute and chronic conditions in mammalian subjects.
    Type: Application
    Filed: September 12, 2013
    Publication date: March 12, 2015
    Applicant: Biosuccess Biotech Co. Ltd.
    Inventors: Zheng Tao Han, Hung-Fong Chen
  • Publication number: 20150057220
    Abstract: Fused aromatic phosphonates of structural formula I are precursors to inhibitors of protein tyrosine phosphatase-1B (PTP-1B). The compounds of the present invention are therefore useful for the treatment in a mammal of a disorder, condition, or disease responsive to inhibition of protein tyrosine phosphatase-1B, including Type 2 diabetes, insulin resistance, a lipid disorder, obesity, Metabolic Syndrome, and cancer.
    Type: Application
    Filed: April 16, 2013
    Publication date: February 26, 2015
    Inventors: Michel Therien, Yves Leblanc, Yongxin Han
  • Publication number: 20150050241
    Abstract: The present invention is directed to methods and compositions employing 9-(4-hydroxy-2-(hydroxymethyl)butyl)guanine (“H2G”) or derivatives or analogs thereof for the treatment of viral diseases, as well as for the treatment of other conditions, including, but not limited to, cancer, chronic fatigue syndrome, Alzheimer's disease, multiple sclerosis and Graves' disease. The H2G or derivative or analog thereof can be administered in a pharmaceutical composition and can be administered with an additional antiviral therapeutic agent or another agent for the treatment of other conditions.
    Type: Application
    Filed: October 30, 2014
    Publication date: February 19, 2015
    Inventors: Fred VOLINSKY, Steven Daniel DONG
  • Publication number: 20150050356
    Abstract: The present invention features methods for treating, stabilizing, preventing, and/or delaying cancer by administering nanoparticles that comprise rapamycin or a derivative thereof. The invention also provides compositions (e.g., unit dosage forms) comprising nanoparticles that comprise a carrier protein and rapamycin or a derivative thereof. The invention further provides combination therapy methods of treating cancer comprising administering to an individual an effective amount of nanoparticles that comprise rapamycin or a derivative thereof and a second therapy.
    Type: Application
    Filed: October 28, 2014
    Publication date: February 19, 2015
    Inventors: Neil P. DESAI, Patrick SOON-SHIONG, Vuong TRIEU
  • Publication number: 20150050239
    Abstract: The present invention provides novel substituted pyrazolone compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.
    Type: Application
    Filed: July 19, 2013
    Publication date: February 19, 2015
    Applicants: Calitor Sciences, LLC, Sunshine Lake Pharma Co., Ltd.
    Inventors: Ning Xi, Yanjun Wu, Min Liao, Yanming Feng
  • Publication number: 20150044217
    Abstract: Described herein are methods and compositions for treating HER2-amplified cancer. The methods include administering to an individual in need thereof ibrutinib.
    Type: Application
    Filed: August 12, 2014
    Publication date: February 12, 2015
    Inventors: Jun CHEN, Joseph J. BUGGY, Laurence ELIAS
  • Publication number: 20150037280
    Abstract: The present invention provides novel substituted pyrazolone compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.
    Type: Application
    Filed: July 19, 2013
    Publication date: February 5, 2015
    Applicants: Sunshine Lake Pharma Co., Ltd., Calitor Sciences, LLC
    Inventors: Ning Xi, Yanjun Wu, Min Liao, Yanming Feng
  • Publication number: 20150025029
    Abstract: A delivery device for a active agent comprises nanoparticles based on a biopolymer such as starch. The delivery device may also be in the form of an aptamer-biopolymer-active agent conjugate wherein the aptamer targets the device for the treatment of specific disorders, such as cancer. The delivery device survives for a period of time in the body sufficient to allow for transport and uptake of the delivery device into targeted cells. The degree of crosslinking can provide a desired release profile of the active agent at, near or inside the target cells. The nanoparticles may be made by applying a high shear force in the presence of a cross linker. The particles may be predominantly in the range of 50-150 nm and form a colloidal dispersion of crosslinked hydrogel particles in water.
    Type: Application
    Filed: September 21, 2012
    Publication date: January 22, 2015
    Inventors: Steven Bloembergen, Ian J. McLennan, Nathan Jones, Areet Krsna Ganesh Shermon, Abdel Elsayed, Juewen Liu
  • Publication number: 20150023868
    Abstract: The present invention is directed to HIF inhibitors and methods of preventing cell proliferation, reducing inflammation, and treating an angiogenic disease or disorders.
    Type: Application
    Filed: February 21, 2014
    Publication date: January 22, 2015
    Applicant: THE GENERAL HOSPITAL CORPORATION
    Inventors: Othon Iliopoulos, Michael Zimmer
  • Publication number: 20150018295
    Abstract: A method is disclosed for the preparation of glycerol esters (triglycerides) of medium-chain length monocarboxylic fatty acids which consists of the reaction of the precursor free fatty acid and glycerol in the presence of a catalyst under partial vacuum. The process preferably uses a metal catalyst such as an oxide or a chloride of tungsten, molybdenum, calcium, zinc, chromium or magnesium. The method of the invention allows the preparation in high yield and high purity (>99.5%) of the final triglyceride. The present method allows the formation of triglycerides without solvent. Are also contemplated, the triglyceride obtained by the method, and the pharmaceutical composition containing the triglyceride as an excipient or as an active ingredient.
    Type: Application
    Filed: February 28, 2013
    Publication date: January 15, 2015
    Inventors: Zacharie Boulos, Jean-Simon Duceppe, Christopher Penney
  • Publication number: 20150010643
    Abstract: This invention relates to a method of treating B cell malignancies, which involves administering to a subject a compound having a structure of formula (I) to cause cell death of a B cell malignancy, thereby treating the B cell malignancy in the subject. Also disclosed are a method of causing cell death of malignant B cells, pharmaceutical compositions and therapeutic systems comprising a compound having a structure of formula (I), and a compound having a structure of formula (I).
    Type: Application
    Filed: February 15, 2013
    Publication date: January 8, 2015
    Applicant: UNIVERSITY OF ROCHESTER
    Inventor: Jiyong Zhao
  • Publication number: 20150010496
    Abstract: Disclosed herein are ?-galactosylceramide (?-GalCer) analogs and compositions thereof, methods of activating invariant Natural Killer T (iNKT) cells using said analogs, methods of treating diseases by activating iNKT cells using said analogs, and combination therapy of said analogs.
    Type: Application
    Filed: November 30, 2012
    Publication date: January 8, 2015
    Inventors: Vincenzo Cerundolo, Gurdyal S. Besra, Liam Cox
  • Publication number: 20150010503
    Abstract: Methods are directed to the treatment of subjects with prostate cancer, in particular those with castration resistant prostate cancer, with glucocorticoid receptor antagonists. The prostate cancer may be one that has become resistant to androgen deprivation therapy, for example, by increase in glucocorticoid receptor expression and/or activity.
    Type: Application
    Filed: February 21, 2013
    Publication date: January 8, 2015
    Applicant: The University of Chicago
    Inventors: Russell Z. Szmulewitz, Suzanne D. Conzen
  • Publication number: 20140370121
    Abstract: Targeting uncontrolled cell proliferation and resistance to DNA damaging chemotherapeutics with at least one reagent has significant potential in cancer treatment. Replication Protein A, the eukaryotic single-strand (ss) DNA binding protein, is essential for genomic maintenance and stability via roles in both DNA replication and repair. Reported herein are small molecules that inhibits the in vitro, in vivo, and cellular ssDNA binding activity of RPA, thereby disrupting the eukaryotic cell cycle, inducing cytotoxicity and increasing the efficacy of chemotherapeutic agents damage DNA, and/or disrupt its replication and/or function. These results provide new insights into the mechanism of RPA-ssDNA interactions in chromosome maintenance and stability. This represents a molecularly targeted eukaryotic DNA binding inhibitor and demonstrates the utility of targeting a protein-DNA interaction as a means of studying the cell cycle and providing a therapeutic strategy for cancer treatment.
    Type: Application
    Filed: August 27, 2014
    Publication date: December 18, 2014
    Inventors: John J. Turchi, Sarah Shuck
  • Publication number: 20140363522
    Abstract: The present invention concerns methods and compositions for the inhibition or reduction of the primary tumor and metastasis by inhibition of fatty acid binding proteins.
    Type: Application
    Filed: May 13, 2014
    Publication date: December 11, 2014
    Inventors: Ernst LENGYEL, Kristin NIEMAN, Hilary KENNY
  • Patent number: 8900565
    Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of histone deacetylase 8 (HDAC8). Also described herein are methods of using such HDAC8 inhibitors, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of HDAC8 activity.
    Type: Grant
    Filed: November 21, 2012
    Date of Patent: December 2, 2014
    Assignee: Pharmacyclics, Inc.
    Inventors: Joseph J. Buggy, Sriram Balasubramanian, Erik Verner, Vincent W. F. Tai, Chang-Sun Lee
  • Publication number: 20140341849
    Abstract: Embodiments of the invention are directed to methods of determining the prognosis of a breast cancer patient by evaluating the activity of the glucocorticoid receptor in tumor cells. Other embodiment include methods of treating breast cancer cells, particularly, chemo-resistant cells, with a glucocorticoid receptor antagonist and an anticancer agent or compound.
    Type: Application
    Filed: August 4, 2014
    Publication date: November 20, 2014
    Inventors: Deng PAN, Masha Kocherginsky, Suzanne D. Conzen
  • Publication number: 20140328863
    Abstract: This invention relates to methods of inducing differential stress resistance in a subject with cancer by starving the subject for a short term, administering a cell growth inhibitor to the subject, or reducing the caloric or glucose intake by the subject. The induced differential stress resistance results in improved resistance to cytotoxicity in normal cells, which, in turn, reduces cytotoxic side-effects due to chemotherapy, as well as improved effectiveness of chemotherapeutic agents.
    Type: Application
    Filed: May 9, 2014
    Publication date: November 6, 2014
    Applicant: University of Southern California
    Inventor: Valter LONGO
  • Patent number: 8877738
    Abstract: The present invention relates to monomeric and multimeric peptidic compounds which have antipathogenic, in particular antiviral or/and antibacterial activity. In a preferred aspect, the peptide compounds of the invention have an activity in respect of a broad spectrum of viruses, both DNA and RNA viruses, irrespective of whether they possess virus envelope or not. Further, the present invention refers to compositions comprising said peptidic compounds for medical use, i.e. for the treatment or prevention of pathogenic, in particular viral or/and bacterial infections.
    Type: Grant
    Filed: August 5, 2010
    Date of Patent: November 4, 2014
    Assignee: Spiderbiotech S.r.L.
    Inventors: Andrea Giuliani, Giovanna Pirri, Lorena Pizzuto, Santo Landolfo, Giorgio Gribaudo, David Lembo, Davide Gibellini
  • Publication number: 20140314746
    Abstract: The invention includes novel methods of treating or preventing fibrosis in a subject afflicted with scleroderma, comprising administering to the subject a therapeutically effective amount of an agent that inhibits formation of at least one inflammasome signaling product in the subject.
    Type: Application
    Filed: March 11, 2014
    Publication date: October 23, 2014
    Applicant: Philadelphia Health and Education Corporation, d/b/a Drexel University College of Medicine
    Inventors: CAROL M. ARTLETT, PETER D. KATSIKIS
  • Publication number: 20140314878
    Abstract: The disclosure provides rifamycin and rifamycin derivative compositions, including rifabutin and rifabutin derivative compositions able to cause drug-sensitization in a cancer cell or inhibition of a cancer cell. The disclosure also provides methods of administering such compositions to cancer cells to sensitize them to drugs, such as chemotherapeutics, or directly inhibit them. The disclosure also provides methods of administering such compositions to increase reactive oxygen species (ROS), particularly superoxides, in cancer cells. The disclosure further provides methods of determining whether a cancer will respond to chemotherapeutics and whether to administer rifamycin or a rifamycin derivative based on ROS levels in cancer cells of a patient.
    Type: Application
    Filed: July 2, 2014
    Publication date: October 23, 2014
    Inventors: James Sacchettini, Niam Zhou, Dwight Baker, Steven A. Maxwell, Deeann Wallis
  • Publication number: 20140315844
    Abstract: Exemplary embodiments of the invention provide methods and compositions relating to a multi-gene signature, and subsets thereof, for predicting whether an individual with breast cancer will respond to chemotherapy based on expression of the genes in the multi-gene signature, as well as for prognosing risk of breast cancer metastasis.
    Type: Application
    Filed: November 27, 2013
    Publication date: October 23, 2014
    Applicant: Celera Corporation
    Inventors: Shirley KWOK, Alice WANG
  • Publication number: 20140309194
    Abstract: This invention provides a therapeutic agent for arthrosis exerting inhibitory effects on articular cartilage destruction and high therapeutic effects on arthrosis. The invention provides a therapeutic agent for arthrosis which comprises, as an active ingredient, cyclic phosphatidic acid or carbacyclic phosphatidic acid.
    Type: Application
    Filed: October 12, 2012
    Publication date: October 16, 2014
    Applicant: SANSHO CO., LTD.
    Inventors: Kimiko Murofushi, Ikuko Masuda, Toshiro Morohoshi
  • Publication number: 20140286902
    Abstract: A pharmaceutical combination comprising a platinum-containing anticancer agent, and an Hsp90 inhibitor according to the following formulae (I) & (Ia), a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables structural formulae are defined herein. Also provided is a method of treating a proliferative disorder such as cancer in a subject in need thereof, using the pharmaceutical combination described herein.
    Type: Application
    Filed: November 1, 2012
    Publication date: September 25, 2014
    Inventor: David Proia
  • Publication number: 20140286938
    Abstract: The present invention relates to spiroketal compounds that are useful in methods of treating or preventing protozoal infections, parasitic infections, bacterial infections, cell proliferative disorders and anti inflammatory disorders. The spiroketal compounds are also useful as immunosuppressive agents, and also in methods of controlling pests.
    Type: Application
    Filed: March 21, 2014
    Publication date: September 25, 2014
    Applicant: EcoBiotics Ltd
    Inventors: Paul Warren Reddell, Victoria Anne Gordon
  • Publication number: 20140271819
    Abstract: Polymorphic forms of onapristone and methods of making and using such polymorphic forms are provided. Crystalline polymorphic forms can be characterized by their X-ray powder diffraction patterns and other properties.
    Type: Application
    Filed: March 11, 2014
    Publication date: September 18, 2014
    Inventor: STEFAN PRONIUK
  • Publication number: 20140255392
    Abstract: The present invention relates to substituted imidazopyridine compounds of general formula (I) in which R3, R5 and A are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: March 28, 2012
    Publication date: September 11, 2014
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Marcus Koppitz, Ulrich Klar, Antje Margret Wengner, Roland Neuhaus, Gerhard Siemeister
  • Publication number: 20140255342
    Abstract: Disclosed is a compound of formula (I), wherein R1, R2, R3, R4, R5, R6, R7 and R8 are as defined in the present application.
    Type: Application
    Filed: May 19, 2014
    Publication date: September 11, 2014
    Applicants: TIANJIN HEMAY BIO-TECH CO., LTD., TIANJIN MICHELE SCI-TECH DEVELOPMENT CO., LTD
    Inventors: Hesheng Zhang, Guanghuai Zeng, Yifei Gao
  • Patent number: 8821877
    Abstract: This method provides a method for reducing HIV-1 viral load in an HIV-1-infected human subject which comprises administering to the subject at a predefined interval effective HIV-1 viral load-reducing doses of (a) a humanized antibody designated PRO 140, or of (b) an anti-CCR5 receptor monoclonal antibody. This invention also provides a method for inhibiting in a human subject the onset or progression of an HIV-1-associated disorder, the inhibition of which is effected by inhibiting fusion of HIV-1 to CCR5+CD4+ target cells in the subject. This invention also provides a method for treating a subject infected with HIV-1 comprising administering to the subject (a) a monoclonal antibody which (i) binds to a CCR5 receptor on the surface of the subject's CD4+ cells and (ii) inhibits fusion of HIV-1 to the subject's CCR5+CD4+ cells, and (b) a non-antibody CCR5 receptor antagonist, in amounts effective to treat the subject.
    Type: Grant
    Filed: November 24, 2010
    Date of Patent: September 2, 2014
    Assignee: CytoDyn Inc.
    Inventors: William C. Olson, Paul J. Maddon, Daniel C. Pevear, Robert J. Israel, Jose D. Murga
  • Publication number: 20140243294
    Abstract: The present invention provides a method of hydroxylating or oxidizing a compound of interest in a subject (e.g., a cytotoxic oxazaphosphorine prodrug), by administering the compound of interest to the subject; and concurrently administering the subject a metalloporphyrin in an amount effective to hydroxylate or oxidize the compound of interest in the subject.
    Type: Application
    Filed: May 8, 2014
    Publication date: August 28, 2014
    Applicant: DUKE UNIVERSITY
    Inventors: Ivan Spasojevic, Michael O. Colvin, Ines Batinic-Haberle, Susan M. Ludeman, Michael P. Gamcsik
  • Publication number: 20140243273
    Abstract: The present invention provides method of treating or lessening the severity of a disease selected from spondyloarthropathy, systemic lupus erythematosus, rheumatoid arthritis, or any combination thereof comprising the administration of a compound of Formula I and an optional co-therapy (e.g., chemotherapy agent, DMARD, or any combination thereof). The present invention also provides a pharmaceutical composition comprising a compound of Formula I, a method of manufacturing a pharmaceutical composition comprising a compound of Formula I, and a method of administering a pharmaceutical composition comprising a solid form of a compound of Formula I.
    Type: Application
    Filed: May 7, 2014
    Publication date: August 28, 2014
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Irina Nikolaevna Kadiyala, Shahla Jamzad, Thomas Carl Hoock, Lori Kell Taylor, Kathryn Lea Sewell
  • Publication number: 20140234254
    Abstract: The present invention provides heteroaromatic derivatives and pharmaceutical acceptable salts and formulations thereof useful in modulating the protein kinase activity, especially phosphatidylinositol 3-kinases (PI3 kinases) and mTOR, and in modulating inter- and/or intra-cellular signaling activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.
    Type: Application
    Filed: February 15, 2014
    Publication date: August 21, 2014
    Applicants: SUNSHINE LAKE PHARMA CO., LTD., CALITOR SCIENCES, LLC
    Inventor: Ning Xi
  • Publication number: 20140234295
    Abstract: Provided herein is a pharmaceutical composition comprising at least one isoflavonoid. Also provided herein are methods of treating cancer, sensitizing cancer cells, and inducing apoptosis in cancer cells by administering such compositions.
    Type: Application
    Filed: November 1, 2011
    Publication date: August 21, 2014
    Applicant: MARSHALL EDWARDS, INC.
    Inventors: George Jeoffreys, Alison Johnson, Andrew Heaton, Ofir Moreno
  • Publication number: 20140227373
    Abstract: A method of improving longevity and/or alleviating a symptom of aging or preventing age related diseases is provided. The method includes a step in which the subject's average and type of daily protein intake, IGF-I, and IGFBP1 levels, and risk factors for overall mortality, cancer and diabetes are determined. With respect to protein consumption, the relative amounts of protein calories from animal and plant sources are determined. A periodic normal calorie or low calorie but low protein fasting mimicking diet with frequencies of every 2 weeks to 2 months is provided to the subject if the subject's average daily protein intake level and type and/or IGF-I levels, and/or IGFBP1 levels is identified as being greater or lower than a predetermined cutoff intake/level and if the subject is younger than a predetermined age. The method is also shown to alleviate symptoms of chemotoxicity.
    Type: Application
    Filed: February 12, 2014
    Publication date: August 14, 2014
    Inventors: Valter D. LONGO, Sebastian BRANDHORST, Morgan Elyse LEVINE
  • Publication number: 20140227284
    Abstract: Described herein are compounds, compositions and methods for treatment of cancer. Also described are methods and uses for identifying subject with cancer that are suitable for treatment with the compounds, composition and methods are described herein. In one aspect of the present invention, there is provided a method of treating a subject having a cancer deficient in NMT2, comprising: administering to said subject an NMT inhibitor.
    Type: Application
    Filed: July 23, 2012
    Publication date: August 14, 2014
    Applicant: PACYLEX PHARMACEUTICALS INC.
    Inventors: Luc G. Berthiaume, Erwan Beauchamp, Conganige Maneka Anne Perinpanayagam, Chuiyee Yap
  • Publication number: 20140227260
    Abstract: The present invention relates to new aminopyrimidine inhibitors of tyrosine kinase activity, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Application
    Filed: April 21, 2014
    Publication date: August 14, 2014
    Applicant: Auspex Pharmaceuticals, Inc.
    Inventor: Chengzhi Zhang
  • Patent number: 8802240
    Abstract: Disclosed are methods of increasing the chemosensitivity of normal and/or chemoresistant tumor or cancer cells using thyroid hormone analogs and/or nanoparticulate or polymeric forms thereof. Also disclosed are methods of increasing radiosensitivity of normal and/or radioresistant tumor or cancer cells using thyroid hormone analogs and/or nanoparticulate or polymeric forms thereof.
    Type: Grant
    Filed: January 6, 2012
    Date of Patent: August 12, 2014
    Assignee: Nanopharmaceuticals LLC
    Inventors: Paul J. Davis, Shaker A. Mousa
  • Publication number: 20140220007
    Abstract: The present invention relates to methods of diagnosing lupus in a patient, as well as methods of monitoring the progression of lupus and/or methods of monitoring a treatment protocol of a therapeutic agent or a therapeutic regimen. The invention also relates to assay methods used in connection with the diagnostic methods described herein.
    Type: Application
    Filed: January 31, 2014
    Publication date: August 7, 2014
    Applicant: MESO SCALE TECHNOLOGIES, LLC
    Inventors: Eli N. Glezer, Mikayla Higgins, John Kenten, George Sigal
  • Publication number: 20140212509
    Abstract: Inhibitors of poly(ADP-ribose)polymerase, ways to make them and methods of treating patients using them are disclosed.
    Type: Application
    Filed: May 24, 2013
    Publication date: July 31, 2014
    Applicant: ABBVIE INC.
    Inventors: Virajkumar B. Gandhi, Vincent L. Giranda, Jianchun Gong, Thomas D. Penning, Gui-Dong Zhu
  • Publication number: 20140212407
    Abstract: The present disclosure relates to the treatment, e.g. reduction, of body fat mass levels for example in overweight and obese subjects. The present disclosure also relates to weight control in a subject where obesity should be avoided. Disclosed herein are methods of reducing body fat mass e.g. reducing obesity or preventing weight gain and agents used in such methods whereby the agents inhibit a sulphur containing amino acid. Also included in the present disclosure include, without being limited to, methods for determining regimes for the treatment of obesity as well as other subject matter.
    Type: Application
    Filed: September 5, 2013
    Publication date: July 31, 2014
    Applicant: Isis Innovation Limited
    Inventors: Amany ELSHORBAGY, Helga Margareta REFSUM
  • Publication number: 20140205680
    Abstract: Methods of treating, preventing or managing cancer, including certain leukemias are disclosed. The methods encompass the administration of enantiomerically pure (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid. Also provided are methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods are also disclosed.
    Type: Application
    Filed: October 17, 2013
    Publication date: July 24, 2014
    Applicant: SUNESIS PHARMACEUTICALS, INC.
    Inventors: Daniel C. Adelman, Jeffrey A. Silverman, Michelle Arkin, Jennifer Hyde, Duncan Walker, Jasmin Wright
  • Publication number: 20140206635
    Abstract: A metal-salen complex compound, which exhibits excellent noninvasiveness and can be efficiently transferred to an affected site, a local anesthetic containing this metal-salen complex compound, and an antineoplastic drug containing this metal-salen complex compound are provided. Regarding the metal-salen complex compound, a metal atom part in each of two molecules of a metal-salen complex or a derivative of the metal-salen complex is dimerized via water, and the metal-salen complex compound is mixed with a base to produce an ointment.
    Type: Application
    Filed: May 10, 2012
    Publication date: July 24, 2014
    Applicants: IHI CORPORATION
    Inventors: Yoshihiro Ishikawa, Haruki Eguchi